Skip to main content

Advertisement

Fig. 2 | BMC Cancer

Fig. 2

From: Stromal ColXα1 expression correlates with tumor-infiltrating lymphocytes and predicts adjuvant therapy outcome in ER-positive/HER2-positive breast cancer

Fig. 2

Survival analysis and ColXα1 expression by IHC in current study (top). The DFS and OS were significantly different between high ColXα1 (103 patients) and low ColXα1 (61 patients) ER+/HER+ tumors. Survival analysis in the TCGA ER+/HER2+ tumor dataset (bottom).. Patients stratified into higher (49 patients) and lower (55 patients) than the median of COL10A1 mRNA expression showed significantly different DFS and OS

Back to article page